HGF
  • Client login
  • Find a specialist
  • Offices
  • Languages
  • Home
  • Services
    • Advertising
    • Copyright & database rights
    • Data protection & privacy
    • Designs
    • Due diligence
    • Formalities & renewals
    • HGF Venture
    • In-house legal support
    • IP litigation
    • Patent Opposition and Appeals
    • Patent term extensions & SPCs
    • Patents
    • Portfolio management
    • Searching & competitor monitoring
    • Strategy
    • Trade marks
    • Trade secrets
    • Transactional IP & commercial support
    • Utility models
  • Business groups
    • Chemistry
    • Law
    • Life sciences
    • Technology & Engineering
    • Trade marks
  • Industries
    • Creative, media & entertainment
    • Energy
    • FemTech
    • Finance
    • Food & drink
    • Healthcare
    • Pharmaceuticals
    • Retail
  • About HGF
    • Our people
    • Knowledge Hub
    • The client experience
    • Diversity, equity and inclusion
    • Sustainability
    • Community engagement
    • HGF ESG Report
  • Knowledge Hub
  • Careers
    • Current vacancies
    • Wellbeing
    • Professional training
    • Working at HGF
  • UP & UPC
    • A new unitary patent and unified patent court
    • Can I opt-out of the UPC?
    • The pros & cons of the opt-out
    • UPC and Agreements
    • What is a Unitary Patent?
    • UPC map
    • UPC Opt-Out Client Portal

Contact Us

Contact an office

Contact a department

Client login
Access your account
Search for a specialist

    Or use the options below to select one or more search areas

    HGF Offices

    • Aberdeen
    • Alderley Park
    • Amsterdam
    • Basel
    • Bern
    • Birmingham
    • Bristol
    • Dublin
    • Edinburgh
    • Glasgow
    • Leeds
    • London
    • Manchester
    • Munich
    • Newcastle
    • Nottingham
    • Paris
    • Rennes
    • Salzburg
    • Sheffield
    • The Hague
    • York
    Aberdeen

    1 Marischal Square,
    Broad Street,
    Aberdeen,
    AB10 1BL

    Office. +44 (0)1224 258 510
    Email. hgf-aberdeen@hgf.com
    Show details
    Alderley Park

    Alderley Park,
    Congleton Rd,
    Alderley Edge,
    Macclesfield,
    SK10 4TG

    Office. +44 (0)161 247 4900
    Email. alderleypark@hgf.com
    Show details
    Amsterdam

    tt. Vasumweg 58D, unit 3.3
    1033 SC Amsterdam
    The Netherlands

    Office. +31(0) 20 809 5628
    Email. hgf-amsterdam@hgf.com
    Show details
    Basel

    OBC Suisse AG
    Aeschengraben 29
    4051 Basel
    Switzerland

    Office. +41 (0)61 225 4480
    Email. docketing@hgf.com
    Show details
    Bern

    sitem-insel AG,
    Freiburgstrasse 3,
    3010 Bern
    Switzerland

    Office. +41 (0)61 225 4480
    Email. docketing@hgf.com
    Show details
    Birmingham

    12th Floor,
    Bank House,
    Birmingham,
    B2 5AL

    Office. +44 (0)121 265 7930
    Email. hgf-birmingham@hgf.com
    Show details
    Bristol

    Origin Workspace,
    40 Berkeley Square,
    Bristol,
    BS8 1HP

    Office. +44 (0)117 244 4144
    Email. hgf-bristol@hgf.com
    Show details
    Dublin

    HGF IP Ltd, Suite 415,
    The Guinness Enterprise Centre (GEC),
    Taylor’s Lane,
    Dublin 8

    Office. +353 1 584 4705
    Email. hgf-dublin@hgf.com
    Show details
    Edinburgh

    80 George Street
    Edinburgh
    EH2 3BU

    Office. +44 (0)131 220 7500
    Email. hgf-edinburgh@hgf.com
    Show details
    Glasgow

    Delta House,
    50 West Nile Street,
    Glasgow,
    G1 2NP

    Office. +44 (0)141 229 5800
    Email. hgf-glasgow@hgf.com
    Show details
    Leeds

    4th Floor,
    1 City Square,
    Leeds,
    LS1 2ES

    Office. +44 (0)113 233 0100
    Email. docketing@hgf.com
    Show details
    London

    5th Floor,
    21 Southampton Row,
    London,
    WC1B 5HA

    Office. +44 (0)207 776 5100
    Email. hgf-london@hgf.com
    Show details
    Manchester

    6th Floor, 4 Hardman Street
    Spinningfields
    Manchester
    M3 3HF

    Office. +44 (0)161 247 4900
    Email. hgf-manchester@hgf.com
    Show details
    Munich

    Neumarkter Str. 18,
    81673 Munich,
    Germany

    Office. +49 (0)89 1259 9600
    Email. munich@hgf.com
    Show details
    Newcastle

    7th Floor, 1 St. James Gate,
    Scotswood Road,
    Newcastle-upon-Tyne,
    NE1 4AD

    Office. +44 (0)191 205 8360
    Email. hgf-newcastle@hgf.com
    Show details
    Nottingham

    BioCity,
    Pennyfoot Street,
    Nottingham,
    NG1 1GF

    Office. +44 (0)115 857 5000
    Email. hgf-nottingham@hgf.com
    Show details
    Paris

    73 Rue de Vaugirard,
    75006 Paris,
    France

    Office. +33(0) 172 355 875
    Email. hgf-paris@hgf.com
    Show details
    Rennes

    2 Rue Claude Chappe,
    35510 Cesson Sévigné,
    France

    Office. +33 (0)256 855 929
    Email. hgf-rennes@hgf.com
    Show details
    Salzburg

    Rudolfskai 48,
    5020 Salzburg,
    Austria

    Office. +43 (0)662 844 289
    Email. hgf-salzburg@hgf.com
    Show details
    Sheffield

    6th Floor
    Fountain Precinct,
    Balm Green,
    Sheffield,
    S1 2JA

    Office. +44 (0)114 274 3700
    Email. hgf-sheffield@hgf.com
    Show details
    The Hague

    Benoordenhoutseweg 46,
    2596 BC The Hague,
    Netherlands

    Office. +31 (0)70 240 0899
    Email. hgf-thehague@hgf.com
    Show details
    York

    Mill House
    North Street
    York
    YO1 6JD

    Office. +44 (0)1904 732 120
    Email. docketing@hgf.com
    Show details

    Language

    • English
    • German
    • French
    Knowledge Hub Legal Updates
    Back to Knowledge Hub

    Legal Updates

    Filter

    Categories

    Reset
    News
    Articles Legal Updates
    Oct 1 2026

    EPO v UPC: How the EPO’s and UPC’s approaches to validity give us food for thought when drafting and prosecuting patent applications destined for Europe (Part 1)

    The Unified Patents Court (UPC) opened its doors on 1 June 2023 and is already having a significant impact on EPO practice. Less than a year after opening, the UPC Court of Appeal (CoA) rendered its decision in 10x Genomics vs. NanoString (UPC_CoA_335/2023), ruling on how claims should be interpreted under the European Patent Convention (EPC). The CoA’s position was at odds with the EPO’s “classical” approach. This inconsistency played an influential role in prompting the EPO to reconsider how c...
    Hsu Min Chung
    Thomas Compton
    Robert Scanes

    EPO v UPC: How the EPO’s and UPC’s approaches to validity give us food for thought when drafting and prosecuting patent applications destined for Europe (Part 1)
    Articles Legal Updates
    Sep 29 2026

    Can foreign manufacturers escape the long arm of the UPC’s jurisdiction?

    In the three years since it became operational, the UPC has established itself as a leading forum for pan-European patent litigation, with a number of decisions raising important questions regarding the full reach of the court’s so-called long-arm jurisdiction.  With that in mind, manufacturers based outside Europe must now give careful consideration to their operations within Europe. The way in which they organise their European sales, supply chains, regulatory functions and group companies may...
    Thomas Compton
    Minghui Sun

    Can foreign manufacturers escape the long arm of the UPC’s jurisdiction?
    Articles Legal Updates
    Sep 28 2026

    UPC CoA confirms jurisdiction over pending European patent application

    Now patent holders may be locked into the UPC system even prior to grant.   The UPC has jurisdiction over European patents that have not been opted out. But what about European patent applications? The UPC Court of Appeal (CoA) [UPC_CoA-90/2026] decided on this point last week, confirming the Paris Central Division’s (CD) [UPC_CFI_799/2026] findings that the UPC’s jurisdiction can extend to European patent applications provided the applications are granted under Article 97(1) EPC1 before the ...
    Hsu Min Chung
    Hsu Min Chung

    Partner & Head of Oppositions and Appeals

    UPC CoA confirms jurisdiction over pending European patent application
    Legal Updates
    Aug 19 2026

    UK Patents Court reinforces the UK threshold for plausibility

    Accord Healthcare Ltd v Novartis AG & Novartis Pharmaceuticals UK Ltd [2026] EWHC 2127 (Pat) (Meade J) – 13 August 2026. Meade J rejected all of Accord's attacks on validity with the result that Novartis' patent and SPC protecting its blockbuster combination product Entresto, were valid.  The Judge held that the claimed valsartan/sacubitril combination was not obvious, that the patent made the claimed therapeutic benefit plausible, and that the invention disclosed a genuine technical contribu...
    Kelly Burrowes
    Kelly Burrowes

    Senior IP Solicitor

    No image available
    Legal Updates
    Mar 9 2026

    UK Court Reflects on Anti-suits, Comity and Coordination in RAND Litigation

    Amazon.Com, Inc. [& ors] v Interdigital VC Holdings, Inc. [& ors] – Meade J –[2026] EWHC 499 (Pat) – 05 March 2026 Mr Justice Meade permitted Amazon to make a declaration limiting its RAND action in the UK, as ordered by the Mannheim Local Division of the UPC.  The Mannheim LD required Amazon to make the declaration in the UPC and UK proceedings to prevent it from being in contempt of the anti-suit injunction the Mannheim LD had ordered.  Meade reluctantly accepted the declaration and provide...
    No image available
    Legal Updates
    Dec 5 2025

    T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

    In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were not entitled to the priority date because the priority application only contained the clinical trial protocol rather than the clinical trial data. The BoA held there was no pointer in the priority application to the specific dose combination claimed, as the dose combination disclosed in the protocol was only to ...
    Joanna Pownall
    Joanna Pownall

    Senior Patent Attorney

    No image available
    Legal Updates
    Nov 21 2025

    UK IPO fees to increase from 1 April 2026

    Whilst the fee changes are subject to parliamentary approval, they are almost certain to take effect – read on to learn more. The United Kingdom Intellectual Property Office (UK IPO) recently announced that it intends to increase its official fees for patents, trade marks and designs from 1st April 2026. These increases are subject to approval by the United Kingdom’s Parliament – however we expect that parliamentary approval will be a mere formality.  As such, clients should expect these inc...
    No image available
    Legal Updates
    Nov 5 2025

    Doubling Up on Added Matter at the UPC

    Following the UPC Court of Appeal (CoA) decision in Abbott v Sibio (APL_39664/2024, 14 February 2025) we now have a second CoA decision on added matter in expert Klein v Seoul Viosys (UPC_CoA_764/2024 & UPC_CoA_774/2024, 2 October 2025). expert Klein v Seoul Viosys is notable as the first judgment on added matter by the CoA on a substantive infringement/validity appeal. Note – HGF Partner Bernhard Ganahl represented expert Klein together with  Dr. Dirk Jestaedt of KRIEGER MES. Both decisi...
    Scott Fletcher
    Scott Fletcher

    Partner & Patent Attorney

    No image available
    Legal Updates
    Sep 12 2025

    T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

    “The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” - r. 3.5. Background EP3113515 was granted with the following independent claim: A hearing device comprising: a processing unit configured to compensate for a hearing loss of a user of the hearing device; a memory unit; and an interface characterized in that the processing unit is configured to: ...
    Alexandra Tyson
    Alexandra Tyson

    Senior Patent Attorney

    T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19
    • Home
      • Sector groups
      • Industries
    • About
      • Our people
      • Find a specialist
    Linkedin
    • Contact
    • Careers
    • UP & UPC
      • A new unitary patent and unified patent court
    • Brexit
    • Client login
    • Make an online payment
    • Knowledge Hub
    • Legal notices & documents
    • Privacy policy
    • Modern slavery
    • Website terms of use
    • Vulnerability disclosure procedure

    Site by Tall
    Copyright © 2026 All rights reserved.